A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Ontology highlight
ABSTRACT: A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
PROVIDER: PRJNA576896 | ENA |
REPOSITORIES: ENA
ACCESS DATA